A 'molecular clock' blood test could help track the growth of tumours around the body, helping to guide the best treatment for individual patients.
A blood test to watch breast cancer’s ‘molecular clock’ could help track the growth of multiple tumours around the body and monitor how they are responding to treatment, new research suggests.
The test, developed by UK scientists, could help identify the most actively-growing tumours as breast cancer spreads around the body, helping to guide the best treatment for individual patients.
The approach has been developed following new results from an innovative rapid autopsy study, the Breast Cancer Now LEGACY Study.
The new study found that the spread of breast cancer to multiple sites follows a traceable, orderly sequence, with the majority of new tumours in distant organs being formed by cancer cells all derived from one cell in the original breast tumour.
While further development is required, scientists at The Institute of Cancer Research (ICR), London and The Royal Marsden NHS Foundation Trust believe the test would be highly sensitive and relatively cheap.
That's because it doesn’t require prior knowledge of the genetic make-up of a patient’s cancer.
Secondary (or metastatic) breast cancer is the term given to breast cancer that has spread to another part of the body, like the bones, liver, lungs, or brain, becoming incurable.
Despite decades of progress, around 11,500 women in the UK each year still die from breast cancer, with almost all of these deaths being caused by secondary breast cancer.
It is estimated that around 35,000 people in the UK are living with secondary breast cancer1.
While secondary breast cancer can be controlled for some time, it currently cannot be cured and patients stay on treatment for the rest of their lives.
Relatively little is known about how and why breast cancer spreads and what can be done to treat it.
In part, this is because secondary breast cancer may form in sites like the brain, liver and bones, so it can be very challenging and painful to take a sample of the tumour for analysis and research.
In a pilot rapid autopsy programme, led by consultant breast surgeon Peter Barry at The Royal Marsden, two women living with secondary breast cancer in London volunteered to donate their cancer tissue for research shortly after their deaths.
The Breast Cancer Now LEGACY study, largely funded by Breast Cancer Now and sponsored by The Royal Marsden NHS Foundation Trust and the ICR, enabled surgeons, pathologists, oncologists and researchers to remove and study secondary tumours rapidly after death.
In so doing, they maintained the integrity of key molecules within tumours (like DNA, RNA and proteins).
As well as taking blood samples and biopsies from all the secondary tumours, whole lymph nodes were also removed, with all tissue being rapidly frozen at -80°C.
Researchers led by Professor Andrea Sottoriva at The ICR then studied the DNA from these secondary breast cancer cells, to try to gain a better understanding of how these cancer cells had changed over time.
LEGACY patient 1 was a 51-year-old woman. She had died 21 months after being diagnosed with de novo secondary breast cancer, meaning that the cancer had already spread from the breast to other parts of the body when she was first diagnosed.
LEGACY patient 2 was a 35-year-old woman who was diagnosed with breast cancer during her pregnancy.
After she had given birth, it was found that the breast cancer had spread to her bones and her lungs, and she died 53 months (around four years) after the initial diagnosis.
Ten of the 12 tumours found throughout patient 1’s body were found to have been established by ‘monoclonal seeding’, meaning that they originated from a single cell from the primary tumour in the breast.
In this patient, the breast cancer first spread to the lung, where a new tumour grew and evolved over time.
The cancer cells from the lung tumour then seeded new tumours in the liver and ovary in two separate waves.
The tumour in the liver then also spread to the ovary and subsequently initiated a secondary tumour in the diaphragm.
The ovary tumour also independently re-seeded the secondary tumour in the liver. Overall, only one liver and one ovary sample weren’t established by monoclonal seeding.
Monoclonal seeding was found to be the only way that breast cancer spread around the body in LEGACY patient 2.
The researchers believe that if monoclonal seeding is the dominant way for breast cancer to spread, it could mean that tracking secondary breast cancer is more achievable than previously thought.
Professor Sottoriva’s team then went on to develop a new kind of blood test for cancer DNA to track how secondary breast cancer has spread.
Over time, cells that actively grow and multiply accumulate molecular marks on their DNA, which appear in distinct patterns.
The scientists found that by analysing cancer DNA fragments in the blood, it was possible to establish the ‘molecular clock’ of cancer cells that the DNA had come from, which identifies how many times they had multiplied.
By analysing these traceable ‘molecular clocks’ and comparing the blood test with the tumours collected during autopsy, the test built a family tree of the cancer cells. The level of cancer cell DNA in the blood then provided information on which secondary tumours were the most active1.
The researchers did, however, find defects in the way cancer cells were adding molecular marks to their DNA in patient 2. This means that further research is needed to understand how common this challenge might be, before a test for clinical use could be developed.
In addition, looking at data from an earlier study of 11 primary breast cancer patients whose disease had spread to the lymph nodes and for whom tissue and blood samples were available, the team confirmed that the ‘molecular clock’ blood test mirrored the genetic make-up of the tumour samples.
The authors propose that the blood test could be used to track how secondary tumours evolve over time, and to monitor their response to a range of treatments.
These include chemo, immunotherapy or targeted therapies, as well as radiotherapy. With further development, it is hoped the ‘molecular clock’ blood test could also be used in the early detection of recurrence or spread following treatment, and may also be relevant for other forms of cancer.
Professor Andrea Sottoriva, Director of Cancer Evolution in the new Centre for Cancer Drug Discovery at The Institute of Cancer Research, London, said:
"Our study sheds light on two of the central challenges in cancer research and treatment – cancer’s lethal ability to adapt and evolve, and its tendency to spread outwards from the initial tumour to other parts of the body.
"The LEGACY study gave us a unique opportunity to analyse the genetic make-up of breast cancer after it has spread to multiple sites in the body, shedding new light on the course of cancer evolution.
"We also identified a brand new way of understanding how the tumour grows and evolves, through analysing ‘molecular clock’ signatures from cancer DNA in the blood.
"We hope to develop a blood test to monitor the evolution of an individual patient’s cancer. And in doing so, to offer hope of effective treatment even where there has been extensive cancer spread."
Peter Barry, Surgical Oncology lead for the Breast Cancer Now LEGACY Study, and Consultant Breast Surgeon at The Royal Marsden, London, said:
"This was a wonderful result of collaboration with a highly innovative team in the ICR led by Professor Sottoriva.
"It points the way to potentially sample one active metastatic site in a patient and then using the molecular clock signature with regular blood tests, test and monitor new treatments in real-time.
"Clearly we need to expand this testing to a larger cohort of patients to see how widely applicable it might just be – in breast cancer patients as well as potentially in patients with other cancer types.
"I am wholeheartedly grateful to the patients and their families who so generously made this study possible."
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, which funded the study, said:
"Studying how and why breast cancer spreads through the body is vital if we are going to find a way to stop it.
"This innovative study, made possible thanks to the patients’ selfless donations, helps us gain insight into how breast cancer spreads from one part of the body to another, paving the way for further research to stop secondary breast cancer.
"The development of a blood test to continuously track how a patient’s cancer is changing and responding to treatment is an exciting step towards being able to offer patients a more personalised treatment plan, which could be readily adapted if a certain therapy is no longer effective.
"However, for this blood test to reach clinics, more testing and refinement in a larger number of people is now required.
"With 11,500 women and 85 men dying from breast cancer every year in the UK, we must find new ways to stop breast cancer from spreading, and to treat it effectively when it does."
Anyone who is worried about their breast cancer spreading can speak to one of our expert nurses, by calling our free Helpline on 0808 800 6000.
Breast Cancer Now’s ambition is that by 2050, everyone diagnosed with breast cancer will live, and be supported to live well.
The charity funds around a quarter of publicly-funded breast cancer research in the UK.
It launched its Unsurvivors campaign in 2019, highlighting that 11,500 people still die from breast cancer every year. As part of that, the charity is demanding urgent change so that everyone with secondary breast cancer can live well for as long as possible.
Breast Cancer Now thanks Walk the Walk for its generous support as one of the founding funders of the LEGACY study for Secondary Breast Cancer.
ENDS
Notes to Editors
- The researchers were also able to assess how well the blood test reflected the disease because they had access to the full extent of the patients’ secondary cancer tissue, thanks to the Breast Cancer Now LEGACY Study.
The full paper is published in Nature Communications.